Effectiveness of Influenza Vaccine for Preventing Laboratory-Confirmed Influenza Hospitalizations in Immunocompromised Adults

K. Hughes, D. Middleton, M. Nowalk, G. Balasubramani, E. Martin, M. Gaglani, H. Talbot, M. Patel, J. Ferdinands, R. Zimmerman, F. Silveira, R. Zimmerman, D. Middleton, F. Silveira, K. Hughes, H. Eng, Theresa M. Sax, Sean G. Saul, Charles Rinaldo, Balasubramani Goundappa, M. Nowalk, Lori Steiffel, J. Williams, Monika Johnson, M. Gaglani, Kempapura Murthy, T. McNeal, Shekar Ghamande, V. Escobedo, Anne Robertson, Lydia Clipper, A. Rao, K-H Chang, Marcus Volz, K. Walker, A. Arroliga, A. Monto, Emily K. Martin, R. Malosh, J. Petrie, A. Lauring, Caroline K. Cheng, H. Segaloff, E. McSpadden, Emileigh Johnson, Rachel K Truscon, L. Lamerato, S. Davis, M. Zervos, H. Talbot, Dayna Wyatt, Yuwei Zhu, Zhouwen Liu, Rendie Mchenry, N. Halasa, Sandra Alvarez Calvillo, Stephanie Longmire, Laura S. Stewart, J. Ferdinands, A. Fry, E. Alyanak, Emily R Smith, Courtney Strickland, Sarah M. Spencer, B. Flannery, J. Chung, Xiyan Xu, Stephen L. Lindstrom, L. Berman, W. Sessions, Rebecca J. Kondor, M. Patel
{"title":"Effectiveness of Influenza Vaccine for Preventing Laboratory-Confirmed Influenza Hospitalizations in Immunocompromised Adults","authors":"K. Hughes, D. Middleton, M. Nowalk, G. Balasubramani, E. Martin, M. Gaglani, H. Talbot, M. Patel, J. Ferdinands, R. Zimmerman, F. Silveira, R. Zimmerman, D. Middleton, F. Silveira, K. Hughes, H. Eng, Theresa M. Sax, Sean G. Saul, Charles Rinaldo, Balasubramani Goundappa, M. Nowalk, Lori Steiffel, J. Williams, Monika Johnson, M. Gaglani, Kempapura Murthy, T. McNeal, Shekar Ghamande, V. Escobedo, Anne Robertson, Lydia Clipper, A. Rao, K-H Chang, Marcus Volz, K. Walker, A. Arroliga, A. Monto, Emily K. Martin, R. Malosh, J. Petrie, A. Lauring, Caroline K. Cheng, H. Segaloff, E. McSpadden, Emileigh Johnson, Rachel K Truscon, L. Lamerato, S. Davis, M. Zervos, H. Talbot, Dayna Wyatt, Yuwei Zhu, Zhouwen Liu, Rendie Mchenry, N. Halasa, Sandra Alvarez Calvillo, Stephanie Longmire, Laura S. Stewart, J. Ferdinands, A. Fry, E. Alyanak, Emily R Smith, Courtney Strickland, Sarah M. Spencer, B. Flannery, J. Chung, Xiyan Xu, Stephen L. Lindstrom, L. Berman, W. Sessions, Rebecca J. Kondor, M. Patel","doi":"10.1101/2020.10.08.20208579","DOIUrl":null,"url":null,"abstract":"Background: Yearly influenza immunization is recommended for immunocompromised (IC) individuals, although immune responses are lower than that for the non-immunocompromised and the data on vaccine effectiveness (VE) in the IC is scarce. We evaluated VE against influenza-associated hospitalization among IC adults. Methods: We analyzed data from adults [≥] 18 years hospitalized with acute respiratory illness (ARI) during the 2017-2018 influenza season at 10 hospitals in the United States. IC adults were identified using pre-specified case-definitions, utilizing electronic medical record data. VE was evaluated with a test-negative case-control design using multivariate logistic regression with PCR-confirmed influenza as the outcome and vaccination status as the exposure, adjusting for age, enrolling site, illness onset date, race, days from onset to specimen collection, self-reported health, and self-reported hospitalizations. Results: Of 3,524 adults hospitalized with ARI, 1,210 (34.3%) had an immunocompromising condition. IC adults were more likely to be vaccinated than non-IC (69.5% vs 65.2%), and less likely to have influenza (22% vs 27.8%). The mean age did not differ among IC and non-IC (61.4 vs 60.8 years old). The overall VE against influenza hospitalization, including immunocompetent adults, was 33% (95% CI, 21% to 44%). VE among IC vs non-IC adults was lower at 5% (-29% to 31%) vs. 41% (27% to 52%) (p<0.05 for interaction term). Conclusions: VE in one influenza season was very low among IC individuals. Future efforts should include evaluation of VE among the different immunocompromising conditions and whether enhanced vaccines improve the suboptimal effectiveness among the immunocompromised.","PeriodicalId":10421,"journal":{"name":"Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America","volume":"38 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"16","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2020.10.08.20208579","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 16

Abstract

Background: Yearly influenza immunization is recommended for immunocompromised (IC) individuals, although immune responses are lower than that for the non-immunocompromised and the data on vaccine effectiveness (VE) in the IC is scarce. We evaluated VE against influenza-associated hospitalization among IC adults. Methods: We analyzed data from adults [≥] 18 years hospitalized with acute respiratory illness (ARI) during the 2017-2018 influenza season at 10 hospitals in the United States. IC adults were identified using pre-specified case-definitions, utilizing electronic medical record data. VE was evaluated with a test-negative case-control design using multivariate logistic regression with PCR-confirmed influenza as the outcome and vaccination status as the exposure, adjusting for age, enrolling site, illness onset date, race, days from onset to specimen collection, self-reported health, and self-reported hospitalizations. Results: Of 3,524 adults hospitalized with ARI, 1,210 (34.3%) had an immunocompromising condition. IC adults were more likely to be vaccinated than non-IC (69.5% vs 65.2%), and less likely to have influenza (22% vs 27.8%). The mean age did not differ among IC and non-IC (61.4 vs 60.8 years old). The overall VE against influenza hospitalization, including immunocompetent adults, was 33% (95% CI, 21% to 44%). VE among IC vs non-IC adults was lower at 5% (-29% to 31%) vs. 41% (27% to 52%) (p<0.05 for interaction term). Conclusions: VE in one influenza season was very low among IC individuals. Future efforts should include evaluation of VE among the different immunocompromising conditions and whether enhanced vaccines improve the suboptimal effectiveness among the immunocompromised.
流感疫苗预防免疫功能低下成人经实验室证实的流感住院的有效性
背景:推荐免疫功能低下(IC)个体每年进行流感免疫接种,尽管免疫应答低于非免疫功能低下者,并且IC中疫苗有效性(VE)的数据很少。我们在IC成人中评估VE与流感相关住院的关系。方法:我们分析了美国10家医院在2017-2018年流感季节因急性呼吸道疾病(ARI)住院的18岁以上成年人的数据。使用预先指定的病例定义,利用电子病历数据确定IC成人。采用多变量logistic回归,以pcr确诊的流感为结果,疫苗接种状态为暴露,对年龄、入组地点、发病日期、种族、发病至标本采集天数、自我报告的健康状况和自我报告的住院情况进行调整,采用检测阴性病例对照设计评估VE。结果:在3524名因ARI住院的成年人中,1210人(34.3%)有免疫功能低下。IC成年人比非IC成年人更有可能接种疫苗(69.5%对65.2%),患流感的可能性更低(22%对27.8%)。IC和非IC患者的平均年龄没有差异(61.4岁vs 60.8岁)。包括免疫功能正常的成年人在内,流感住院的总体VE为33% (95% CI, 21%至44%)。IC与非IC成人的VE较低,分别为5%(-29%至31%)和41%(27%至52%)(相互作用期p<0.05)。结论:IC人群流感季节VE极低。未来的工作应包括评估不同免疫功能低下人群的VE,以及增强疫苗是否能改善免疫功能低下人群的次优效果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信